Viz.ai has recently partnered with Avincenna.ai to launch its artificial intelligence-powered smart care solution for patients suffering from fatal pulmonary embolism and aortic disease. The new platform would assist patients in making better decisions regarding the treatment of such fatal diseases.
Both the companies plan to integrate Viz.ai’s algorithm for pulmonary embolism and different types of aortic diseases with Avincenna.ai’s intelligence care coordination system to develop a wholesome solution for all kinds of patient needs.
Dr. Richard Saxon, a radiologist at Tri-City Medical center, said, “The addition of artificial intelligence-powered workflows will decrease the time from diagnosis to treatment and help to coordinate care for patients suffering from life-threatening pulmonary embolism and aortic disease. It will also help to facilitate faster and easier treatment decisions across health systems, and should improve outcomes for patients.”
Viz.ai is a San Francisco-based company founded in 2016. It is a leading provider of artificial intelligence-driven healthcare software that helps patients and doctors effectively treat several diseases. Many global leaders have invested in Viz.ai, like Google Ventures, Kleiner Perkins, Greenoaks, and Innovation Endeavors.
CEO and co-founder of Viz.ai, Chris Mansi, said, “We are delighted to partner with Avicenna.ai to bring intelligent care coordination to the peripheral vascular and vascular fields. This will form part of a broader Viz platform, where any patient with a life-threatening disease can benefit from artificial intelligence-powered triage, fast mobile communication, and synchronized care coordination.”
He further mentioned that this partnership of the two companies would help innumerable patients avail advantage of artificial intelligence and help hospitals generate better clinical results.
Cyril Di Grandi founded Avicenna.ai in 2018. The startup specializes in artificial intelligence-powered imaging solutions for radiology applications. Earlier, the company received approval from the Food and Drug Administration for its solution for neurovascular emergencies.